secwatch.observer — SEC 8-K summary
======================================

Issuer:     CODEXIS, INC. (CDXS)
CIK:        0001200375
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001193125-24-248698
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Codexis Q3 product rev $11.2M, net loss narrows to $20.6M; cash $90.3M
----------------------------------------------------------------------

- Total revenues $12.8M vs $9.3M YoY; product rev $11.2M vs $5.4M; R&D rev $1.7M vs $3.9M.
- Net loss $20.6M ($0.29/sh) vs $34.9M ($0.50/sh) YoY; product gross margin 61% vs 58%.
- Raised $31M via ATM in Oct 2024; cash $90.3M, expects to fund operations into 2027.
- Appointed Georgia Erbez CFO and Alison Moore new CTO (former Allogene CTO).
- Licensed genomics enzyme portfolio to Alphazyme/Maravai; eligible for sales-based royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1200375/000119312524248698/0001193125-24-248698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1200375/000119312524248698/d896975d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-248698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer